Will the second SGLT-2 insurance benefit decision form competition against DPP-4?

For the second time in the domestic market, a SGLT-2inhibitor is going to receive the health insurance from the 1^st. The benefited drug is ‘Suglat(generic name: ipragliflozin). Its insured drug price will be KRW 705 per tab, applied when it is administered singular or in combination with metformin depending on a degree of glycated hemoglobin.

Although monopolism of ‘Forxiga(generic name: dapag...